Company Overview and News
Earnings: Power Grid Corporation has reported 4.6 percent rise in its Q4FY18 net profit at Rs 2,004.7 crore against Rs 1,916.4 crore in the same quarter last fiscal.
500325 RELIANCE 532712 533278 STAR RCOM 532483 RIGD GODFRYPHLP HDFCBANK CLNDY RLNIY BANKINDIA IBN 532967 538835 KIRIINDUS DCMSRMIND 532941 532149 BHEL CNRYY 532531 ICICIBANK CORDSCABLE HDB 532174 500180 BRHTY INTELLECT 500103 534809 PCJEWELLER 500163 CANBK 523369 COALINDIA
New Delhi: Drug firm Strides Shasun has sought shareholders’ nod to change its name to Strides Pharma Science. This is the second time in three years time, when the name of the company will change.
Earnings Reaction: Godfrey Phillips India's March quarter profit dropped 22.8 percent year-on-year to Rs 43.1 crore and revenue from operations declined 37.6 percent to Rs 543.3 crore.
500325 RELIANCE 532955 532712 STAR RCOM RIGD GODFRYPHLP HDFCBANK RLNIY BANKINDIA IBN 538835 DCMSRMIND 532941 532149 BHEL 539207 532531 ICICIBANK CORDSCABLE HDB 532174 500180 BRHTY INTELLECT 500103 RECLTD 500163 523369 MANPASAND
Earnings: M&M's March quarter earnings beat analyst expectations as profit grew by 50 percent year-on-year to Rs 1,155 crore and revenue increased 25.6 percent to Rs 13,189 crore during the quarter.
500325 AUROPHARMA RELIANCE 532955 532712 533106 STAR RCOM OIL RIGD HDFCBANK RLNIY BANKINDIA 524804 IBN 538835 532941 532149 BHEL 539207 532531 ICICIBANK CORDSCABLE HDB 532174 500180 ARBQY BRHTY INTELLECT 500103 RECLTD MANPASAND
Market Update: Benchmark indices as well as broader markets are in a consolidation mode after sharp rally seen in previous three consecutive sessions. Investors closely monitor the movement in crude oil prices and rupee.
500325 AUROPHARMA RELIANCE 532955 532712 533106 STAR RCOM OIL RIGD 519183 GREENPLY HDFCBANK RLNIY IPCALAB 524804 IBN 538835 BHEL 539207 532531 ICICIBANK 524494 HDB 532174 500180 ARBQY 526797 BRHTY INTELLECT 500103 RECLTD MANPASAND ADFFOODS
Drug firm Strides Shasun has sought shareholders' nod to change its name to Strides Pharma Science. This is the second time in three years time, when the name of the company will change.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to NSE:STAR / STRIDES ARCOLAB LTD. on message board site Silicon Investor.